Experimentally, navitoclax kills cells inside a BAX/BAK-dependent method and leads to regression of lymphoid tumors in xenograft styles. The combination of navitoclax and irradiation exhibited a strong synergy whatever the p53 mutation status. (a) Probably the most synergistic area scores to the navitoclax–irradiation combination across thirteen HNSCC cell lines. (b) https://kedarp405bob6.wikilima.com/user